Carr Patricia's Form 4 filing
Jazz Pharmaceuticals plc (JAZZ) · filed Mar 7, 2023
- Accession no.
- 0001765581-23-000026
- Filed
- Mar 7, 2023
- Trade date
- Mar 3-5, 2023
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market sales total $161.6K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Carr PatriciaCIK 0001784606 | Officer (SVP, Chief Accounting Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 3, 2023 | Ordinary Shares | AGrant or awardAcquired | +2,523 | $0.00 | $0 | 8,457 | Direct | |
| Mar 5, 2023 | Ordinary Shares | SSaleDisposed | −1,148 | $140.76F3 | −$161,592.48 | 7,309 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $140.7559 to $140.7631. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
Referenced by the price of 1 transaction in Table I.